Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients

This study is testing a procedure called Revita DMR (duodenal mucosal resurfacing) — a minimally invasive endoscopic treatment that remodels the lining of the upper small intestine — to see if it helps improve blood sugar control in people with type 2 diabetes whose current medications are not enough. **You may be eligible if...** - You are 18–75 years old with type 2 diabetes - You are not using insulin - You are on 2 or more stable diabetes medications (such as metformin, SGLT-2 inhibitors, GLP-1 agonists, or DPP-4 inhibitors) at the maximum tolerated dose for at least 12 weeks - Your BMI is between 24 and 40 - Your HbA1c (long-term blood sugar marker) is between 7.5% and 10% **You may NOT be eligible if...** - Your blood sugar is dangerously high (above 270 mg/dL after fasting) - You have type 1 diabetes or severe kidney, liver, or heart disease - You have a history of stomach or intestinal surgery - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.